Generation Bio (NASDAQ:GBIO) PT Set at $5.50 by Wedbush

Generation Bio (NASDAQ:GBIO) received a $5.50 price objective from Wedbush in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 2.61% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Canaccord Genuity Group lifted their target price on Generation Bio from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 18th. Jefferies Financial Group lowered shares of Generation Bio from a “buy” rating to a “hold” rating and cut their target price for the stock from $11.00 to $5.00 in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Generation Bio in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Generation Bio in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Generation Bio presently has a consensus rating of “Hold” and a consensus target price of $8.88.

Generation Bio Stock Performance

Shares of NASDAQ:GBIO opened at $5.36 on Tuesday. The firm has a market cap of $36.13 million, a PE ratio of -0.57 and a beta of 1.96. Generation Bio has a 52 week low of $3.00 and a 52 week high of $12.50. The firm’s fifty day moving average is $5.59 and its 200-day moving average is $5.15.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $0.66 million. Sell-side analysts forecast that Generation Bio will post -1.75 EPS for the current year.

Institutional Investors Weigh In On Generation Bio

Several large investors have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its stake in Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after acquiring an additional 407,843 shares during the last quarter. Militia Capital Partners LP bought a new position in Generation Bio during the second quarter valued at $174,000. Nuveen LLC purchased a new stake in Generation Bio in the first quarter worth $69,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Generation Bio in the second quarter valued at $47,000. Finally, Marshall Wace LLP purchased a new position in shares of Generation Bio during the 2nd quarter valued at $37,000. 95.22% of the stock is owned by hedge funds and other institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.